CorVel vs Veracyte
CorVel reported revenue of $958 million in fiscal 2026, 1.9 times Veracyte's $517 million in fiscal 2025. CorVel's revenue grew 7.0% in its latest year, and Veracyte's grew 16.0%. Free cash flow was $110 million at CorVel and $127 million at Veracyte. Their fiscal years end in different months (March 31 and December 31), so the periods don't line up exactly.
Side by side
| CorVel | Veracyte | |
|---|---|---|
| Latest fiscal year | FY2026, Mar 31, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $958M | $517M |
| Revenue growth | 7.0% | 16.0% |
| Revenue growth a year, last 5 years | 11.6% | 34.5% |
| Gross margin | 24.3% | 70.1% |
| Operating margin | — | 11.2% |
| Net margin | 11.5% | 12.8% |
| Free cash flow | $110M | $127M |
| Free cash flow margin | 11.5% | 24.5% |
| Return on capital | — | 6.1% |
| Net debt to EBITDA | — | −4.6x |
| Dividends and buybacks | $56M | $0M |
| Change in diluted share count | −0.7% | 3.1% |
| Last close | $83.16 | $24.16 |
| P/E at the last close | 34.9× | 15.7× |
| Insider trades, last 12 months | sold $21.2 million | sold $19.6 million |
| Piotroski F-score | — | 6 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CorVelVeracyte
Operating margin
Percent of revenue
CorVelVeracyte
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CorVelVeracyte